Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mulberry total alkaloid tablets with or without metformin in polycystic ovary syndrome
ChiCTR2200065097Phase 4Completed
- Sponsor
- Wuxi People's Hospital
- Start
- Oct 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mulberry total alkaloid tablet in polycystic ovary syndrome (PCOS) (5 arms), sponsored by Wuxi People's Hospital. Primary endpoints: Testosterone and Sex hormone binding globulin. Started Oct 2022; status: completed.
02
Drugs
mulberry total alkaloid tablet
03
Conditions
polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on ChiCTR2200065097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065097.